Spironolactone

Generic Name: Spironolactone

Brand Names: Aldactazide, Aldactone, Carospir, Qaialdo

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₃₂O_₄S

CAS Number: 52-01-7

Unique Ingredient Identifier: 27O7W4T232

Background: Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered. It is indicated to treat several ...

Indication: Spironolactone is indicated for the treatment of the following conditions:

As spironolactone has antiandrogenic activity, its off-label uses include the treatment of hirsutism, female pattern hair loss, and adult acne vulgaris.

Associated Conditions: Edema, Hypertension, Primary Aldosteronism, Primary Hyperaldosteronism, Secondary hyperaldosteronism, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Idiopathic hyperaldosteronism, Refractory Edema

Associated Therapies: Perioperative drug treatment, Maintenance therapy

Clinical Trials

Spironolactone for Reducing Proteinuria in Diabetic Nephropathy

Not Applicable

Completed

Conditions: Diabetic Nephropathy

Interventions: Drug: spironolactone

First Posted Date: 2007-07-10

Last Posted Date: 2008-10-17

Lead Sponsor: US Department of Veterans Affairs

Target Recruit Count: 30

Registration Number: NCT00498537

Locations: 🇺🇸
VA Medical Center, Dayton, Dayton, Ohio, United States

The Efficacy of Spironolactone in Patients With Resistant Hypertension

Phase 2

Terminated

Conditions: Hypertension

First Posted Date: 2007-02-02

Last Posted Date: 2010-12-06

Lead Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust

Target Recruit Count: 40

Registration Number: NCT00430794

Locations: 🇬🇧
Clinical Research Facility, Royal Hallamshire Hospital, Sheffield, South Yorkshire, United Kingdom

Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone

Phase 4

Completed

Conditions: Heart Failure
Ventricular Dysfunction, Left

Interventions: Drug: Captopril
Drug: Enalapril
Drug: Lisinopril
Drug: Ramipril
Drug: Trandolapril
Drug: Bisoprolol
Drug: Carvedilol
Drug: Metoprolol succinate
Drug: Candesartan
Drug: Valsartan
Drug: Eplerenone
Drug: Spironolactone
Drug: Diuretics
Drug: HF treatment according to Swedish guidelines
Procedure: Blood samples
Procedure: The Kansas City Cardiomyopathy Questionnaire (KCCQ)

First Posted Date: 2006-10-25

Last Posted Date: 2012-06-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 252

Registration Number: NCT00391846

Locations: 🇸🇪
Research Site, Vaxjo, Sweden

Autoregulation of Glomerular Filtration Rate in Patients With Type 1 Diabetes During Spironolactone Therapy

Phase 4

Completed

Conditions: Hypertension

First Posted Date: 2006-06-09

Last Posted Date: 2008-06-05

Lead Sponsor: Steno Diabetes Center Copenhagen

Target Recruit Count: 17

Registration Number: NCT00335413

Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis

Phase 4

Conditions: Liver Cirrhosis
Portal Hypertension

Interventions: Drug: propranolol
Drug: spironolactone

First Posted Date: 2006-06-02

Last Posted Date: 2010-06-04

Lead Sponsor: Hvidovre University Hospital

Target Recruit Count: 22

Registration Number: NCT00332904

Locations: 🇩🇰
Department of Clinical Physiology and Nuclear Medicine, and Department for Gastrointestinal Medicine, Hvidovre Hospital, Hvidovre, Denmark

Spironolactone Safety in Dialysis Patients

Phase 4

Withdrawn

Conditions: End Stage Renal Disease
Congestive Heart Failure

Interventions: Drug: spironolactone

First Posted Date: 2006-05-22

Last Posted Date: 2020-10-22

Lead Sponsor: State University of New York - Upstate Medical University

Registration Number: NCT00328809

Locations: 🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States

Spironolactone in Diabetic Nephropathy

Phase 4

Completed

Conditions: Diabetic Nephropathy

First Posted Date: 2006-04-25

Last Posted Date: 2006-04-25

Lead Sponsor: Steno Diabetes Center Copenhagen

Target Recruit Count: 48

Registration Number: NCT00317954

Locations: 🇩🇰
Steno Diabetes Center, Gentofte, Denmark

Examining the Effect of Different Diuretics on Fluid Retention in Diabetics Treated With Rosiglitazone.

Phase 4

Completed

Conditions: Diabetes Mellitus

First Posted Date: 2006-03-24

Last Posted Date: 2016-09-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 388

Registration Number: NCT00306696

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Mineralocorticoid Receptor in the Treatment of Severe Depression

Not Applicable

Completed

Conditions: Major Depression

First Posted Date: 2006-02-23

Last Posted Date: 2017-05-30

Lead Sponsor: Universitätsklinikum Hamburg-Eppendorf

Target Recruit Count: 65

Registration Number: NCT00295347

Locations: 🇩🇪
University Hospital Hamburg-Eppendorf, Hamburg, Germany

Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?

Phase 2

Completed

Conditions: Chronic Kidney Disease
Cardiovascular Disease

Interventions: Drug: Spironolactone
Drug: Placebo

First Posted Date: 2006-02-14

Last Posted Date: 2008-05-21

Lead Sponsor: University Hospital Birmingham

Target Recruit Count: 120

Registration Number: NCT00291720

Locations: 🇬🇧
University Hospital Birmingham, Birmingham, West Midlands, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy